
(MedPage Today) — Bypassing its standard pathways for scientific discussions, FDA has recently held a slew of so-called “expert panels” that sidestep legal procedures and ethics guardrails, raising concern about cherry-picking of experts and evidence…
Source link : https://www.medpagetoday.com/washington-watch/fdageneral/116662
Author :
Publish date : 2025-07-24 20:36:00
Copyright for syndicated content belongs to the linked
Source.